The vision of the adapt valve in operation has increased my enthusiasm for the TAVR release.
This is from Patersons report in April;
In our view, the curved patch and TAVR valve are likely to make material contributions to AHZ’s bottom line within the first full year of their launch. The TAVR valve in particular has sales potential that could significantly exceed that of CardioCel.
Bring on 2018 and the launch of these two.
ADAPT TAVR -Just Better, page-14
-
- There are more pages in this discussion • 75 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.65 |
Change
-0.060(0.38%) |
Mkt cap ! $300.8M | |||
| Open | High | Low | Value | Volume |
| $15.72 | $15.85 | $15.51 | $1.660M | 117.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 312 | $15.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.65 | 626 | 1 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |